Aethlon Medical to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Rhea-AI Summary

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology firm, will be presenting at the HC Wainwright 22nd Annual Global Investment Conference on Monday, Sept. 14, 2020, at 2:00 p.m. EDT. The presentation will be led by CEO Timothy C. Rodell and will be available for replay for 90 days post-presentation. Aethlon’s primary focus is the Hemopurifier^®, a breakthrough immunotherapeutic device targeting cancer and life-threatening viral infections. The Hemopurifier aims to reduce tumor-derived exosomes that contribute to immune suppression and metastasis.

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, today announced that Timothy C. Rodell, M.D., Chief Executive Officer, is scheduled to provide an overview of the Company on Monday, Sept. 14, at 2:00 p.m. EDT

Replays of the presentation will be aired live and available for 90 days. The reply can be accessed at https://wsw.com/webcast/hcw7/aemd/1577311 and the investor relations section of Aethlon Medical's website at www.aethlonmedical.com.

About Aethlon Medical, Inc. and the Hemopurifier^®
Aethlon is focused on addressing unmet needs in global health. The Aethlon Hemopurifier is a clinical- stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. In cancer, the Hemopurifier is designed to deplete the presence of circulating tumor-derived exosomes that promote immune suppression.

These tumor derived exosomes also seed the spread of metastases and inhibit the benefit of leading cancer therapies. The Hemopurifier^® is an FDA designated "Breakthrough Device" related to the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease cancer. The Hemopurifier also holds a Breakthrough Device designation related to life-threatening viruses that are not addressed with approved therapies.

Aethlon also owns 80% of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor cancer and neurological disease progression. Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com.

Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc. 
858-459-7800 x3300
Jfrakes@aethlonmedical.com

Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251

Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com 
212-966-3650

View original content:http://www.prnewswire.com/news-releases/aethlon-medical-to-present-at-the-hc-wainwright-22nd-annual-global-investment-conference-301124812.html

SOURCE Aethlon Medical, Inc.

FAQ

What is Aethlon Medical presenting at the HC Wainwright conference on Sept. 14, 2020?

Aethlon Medical, Inc. will present an overview of the company and its technologies, including the Hemopurifier device.

Who is the CEO of Aethlon Medical?

The CEO of Aethlon Medical is Timothy C. Rodell.

What is the Hemopurifier and why is it significant?

The Hemopurifier is an immunotherapeutic device designed to target cancer and viral infections, recognized as a FDA Breakthrough Device.

How can I access the Aethlon Medical presentation after Sept. 14, 2020?

The presentation can be accessed through a provided link and will be available for 90 days following the live event.

What does Aethlon Medical focus on?

Aethlon Medical focuses on developing medical devices to diagnose and treat life and organ-threatening diseases.